Čelešnik Helena, Gorenjak Mario, Krušič Martina, Crnobrnja Bojana, Sobočan Monika, Takač Iztok, Arko Darja, Potočnik Uroš
Faculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova ulica 17, 2000 Maribor, Slovenia.
Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia.
Cancers (Basel). 2024 Sep 16;16(18):3171. doi: 10.3390/cancers16183171.
Breast cancer (BC) comprises multiple subtypes with distinct molecular features, which differ in their interplay with host immunity, prognosis, and treatment. Non-invasive blood analyses can provide valuable insights into systemic immunity during cancer. The aim of this study was to analyze the expression of transcriptional isoforms in peripheral blood mononuclear cells (PBMCs) from BC patients and healthy women to identify potential BC immune biomarkers. RNA sequencing and isoform-level bioinformatics were performed on PBMCs from 12 triple-negative and 13 luminal A patients. Isoform expression validation by qRT-PCR and clinicopathological correlations were performed in a larger cohort (156 BC patients and 32 healthy women). Transcriptional analyses showed a significant ( < 0.001) decrease in the isoform in PBMCs of BC compared to healthy subjects, indicating disease-related expression changes. The decrease was associated with higher ctDNA and Ki-67 values. The levels of the transcriptional isoform may have the potential to distinguish between BC and healthy subjects. The downregulation of in breast cancer is associated with higher proliferation and ctDNA shedding. Specialized bioinformatics analyses such as isoform analyses hold significant promise in the detection of biomarkers, since standard RNA sequencing analyses may overlook specific transcriptional changes that may be disease-associated and biologically important.
乳腺癌(BC)包含多种具有不同分子特征的亚型,它们在与宿主免疫的相互作用、预后和治疗方面存在差异。非侵入性血液分析可为癌症期间的全身免疫提供有价值的见解。本研究的目的是分析乳腺癌患者和健康女性外周血单个核细胞(PBMC)中转录异构体的表达,以确定潜在的乳腺癌免疫生物标志物。对12例三阴性和13例腔面A型患者的PBMC进行了RNA测序和异构体水平的生物信息学分析。通过qRT-PCR进行异构体表达验证,并在更大的队列(156例乳腺癌患者和32例健康女性)中进行临床病理相关性分析。转录分析显示,与健康受试者相比,乳腺癌患者PBMC中该异构体显著减少(<0.001),表明存在与疾病相关的表达变化。这种减少与更高的循环肿瘤DNA(ctDNA)和Ki-67值相关。该转录异构体的水平可能有潜力区分乳腺癌患者和健康受试者。乳腺癌中该异构体的下调与更高的增殖和ctDNA释放相关。诸如异构体分析等专门的生物信息学分析在生物标志物检测方面具有重大前景,因为标准的RNA测序分析可能会忽略可能与疾病相关且具有生物学重要性的特定转录变化。